Cipla Ltd.

CIPLA

Market Cap
₹1,11,808 Cr.
P/E
30.15

Cipla Ltd.

Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics

12 Yes

Positive for this company

2 Neutral

Neutral for this company

3 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE
Latest
11.97%
3yr Average
12.39%
5yr Average
11.43%
Net Profit Margin
Latest
12.31%
3yr Average
12.14%
5yr Average
10.96%
ROCE
Latest
18.06%
3yr Average
17.5%
5yr Average
15.25%
Debt to Equity
Latest
0.02
3yr Average
0.05
5yr Average
0.12
Market Share
1.36% (as of Jul 22)
Anti - Diabetes - Market Share
7.76% (as of Jul 22)
Anti-Infectives - Market Share
0.96% (as of Nov 21)
Anti-Malarial - Market Share
5.93% (as of Nov 21)
Antineo Plastic - Market Share
0.79% (as of Nov 21)
Blood Related - Market Share
4.48% (as of Jul 22)
Cardiovascular - Market Share
2.19% (as of Nov 21)
Dermatology - Market Share
0.55% (as of Nov 21)
Endocrinology - Market Share
2.37% (as of Jul 22)
Gastro-Intestinal - Market Share
1.85% (as of Nov 21)
Gynecology - Market Share
2.97% (as of Nov 21)
Neurological - Market Share
8.92% (as of Nov 21)
Ophthalmology - Market Share
1.94% (as of Nov 21)
Pain - Market Share
5.30% (as of Dec 22)
Pharmaceutical Sector - Market Share
23.76% (as of Nov 21)
Respiratory - Market Share
4.31% (as of Jul 22)
Sex Stimulants - Market Share
0.07% (as of Oct 19)
Stomatological - Market Share
18.51% (as of Nov 21)
Urology - Market Share
0.06% (as of Jul 22)
Vaccines - Market Share
0.62% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Wise Break-Up - Domestic

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Global API

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Break-Up -Global API

locked
Source
|
Latest
|
locked
Historic

Operating Profit Break-Up

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • US DMF Filings (.)
      Source
    • Number of ANDA's Filed in USA (.)
      Source
    • Number of ANDA's Approved By USFDA (.)
      Source
    • Domestic Sales Growth - YoY (%)
      Source
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Brands
    Bronco cough syrup
    Coryx
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Cipla Ltd.
    View the discussion on ValuePickr
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline